Shyonaka (Oroxylum indicum): The Dashamoola Tree

TL;DR

Shyonaka is Oroxylum indicum, and its root bark is one of the ten roots of Dashamoola. Ayurveda uses it for inflammation and rheumatic complaints. Direct evidence is limited to a rat study. Root- and stem-bark decoctions both significantly suppressed carrageenan-induced paw edema. No human trials exist, and the Government of India lists the tree as vulnerable.

What it is

Shyonaka is a small-to-medium deciduous tree, Oroxylum indicum (family Bignoniaceae), found across India and Southeast Asia. It is recognizable by its large sword-like seed pods. In Ayurveda, shyonaka is the accepted botanical for one of the five tree-root ingredients of Dashamoola, the ten-root group that anchors many classical formulations.

Because harvesting roots kills the tree, India's Ayurvedic Pharmacopoeia recommends the stem bark as a substitute for the root bark, a decision supported by the animal research described below. The tree has also been officially categorized as vulnerable by the Government of India.

Traditional use

Shyonaka's root bark is used in Dashamoola preparations, both as a decoction (kwatha) and powder (churna). Traditional indications include sotha (swelling and inflammation) and amavata (rheumatic conditions), applied both internally and externally. It appears as an ingredient in classical formulations including Dasamoolaristam and Chyavanaprasa. Its flavones, including baicalein, chrysin, and oroxylum-A, plus ellagic acid, have been noted in phytochemical reports.

What modern research says

Anti-inflammatory effect in a rat model (animal study)

A 2011 study in the Journal of Ayurveda and Integrative Medicine compared root-bark and stem-bark decoctions of Oroxylum indicum in the standard carrageenan-induced paw-edema model, using 18 rats in three groups. Both decoctions significantly suppressed edema compared to control, and the stem bark performed at least as well as the root bark. That is the whole direct-efficacy record: 18 rats. The authors concluded that stem bark can replace root bark in Dashamoola formulations, sparing the tree from being uprooted, and explicitly called for clinical studies to follow up.

Seed-extract activities (in vitro and animal work)

The same study's introduction notes that the seed extract has been investigated for antimicrobial, analgesic, antitussive, and anti-inflammatory activity, citing a 1998 Phytomedicine report on its anti-inflammatory action. These are ingredient-level, preclinical observations, not clinical findings.

What the evidence does not support (yet)

No human trials of shyonaka have been published. Its traditional anti-inflammatory and anti-rheumatic uses remain clinically unproven, and the rat findings cannot be transferred to human dosing or outcomes. Claims beyond inflammation and pain (such as anticancer effects) have no demonstrated basis in the reviewed literature.

Safety & contraindications

No human safety data were identified for shyonaka decoctions or extracts. There are no published toxicity studies in humans, so safe doses for adults, children, pregnant women, and breastfeeding mothers are unknown. Its traditional Ushna (heating) potency and Pitta-aggravating classification mean practitioners classically avoid it in high-Pitta conditions. The tree's vulnerable conservation status means only sustainably sourced, stem-bark-based material should be used. Anyone considering shyonaka preparations should consult a qualified Ayurvedic practitioner.

FAQs

What is shyonaka?

Shyonaka is the root bark of Oroxylum indicum, a Bignoniaceae tree and one of the five tree roots of Dashamoola. The Ayurvedic Pharmacopoeia of India now recommends using its stem bark instead of root bark to protect the species.

Is stem bark really equivalent to root bark?

In one rat study on inflammatory swelling, stem-bark decoction suppressed edema at least as well as root-bark decoction, which is why the API accepted the substitution. That equivalence has not been tested in humans.

Does shyonaka help arthritis?

It is used traditionally for amavata (rheumatic complaints), but no human trial has tested it for arthritis. The evidence is limited to animal models of inflammation.

Why is it called vulnerable?

India has officially categorized Oroxylum indicum as vulnerable, largely because root harvesting destroys the tree. Using the API-recommended stem bark is the conservation-conscious choice.

No established human dose exists. The rat study used a decoction based on a traditional human equivalent of about 25 g of root bark in 50 mL taken three times daily, but that is a traditional equivalence, not a validated clinical dose. This article follows an editorial rule: no dosage without a pharmacopoeial or clinical-trial citation.

Can I take it during pregnancy?

There are no safety data for pregnancy or breastfeeding. Classical texts do not provide modern safety reassurance, so it should be avoided unless a qualified practitioner supervises its use.

Sources

Disclaimer

This article is for education only and is not medical advice. Shyonaka has no human-trial evidence behind it, no established dose, and no known safety profile in pregnancy or childhood. Consult a qualified Ayurvedic practitioner or clinician before using it, especially since the species is officially vulnerable and sourcing matters.